Scholarlink

<p>In 2011, meibomian gland dysfunction (MGD) was officially recognized as a condition that necessitated treatment with the goal of improving ocular symptoms. This was a tipping point in the understanding of MGD and the need for treatment. After 2011, there was an exponential increase in the research of MGD and treatment modalities. This commentary aims to provide information for clinicians to understand the value of in-office treatments with LipiFlow and the inherent differences in efficacy, patient/doctor experience, compliance, and safety of other treatment modalities. Also, the aim of this commentary is to describe how LipiFlow Thermal Pulsation System contributed to the evolution of MGD management by transforming therapeutic gland expression from an underutilized intervention into a widely adopted, evidence-based standard of care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LipiFlow and the Transformation of Therapeutic Meibomian Gland Expression into Routine Clinical Practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Caroline A. Blackie,
  • David Murakami,
  • Eric Donnenfeld,
  • Heather S. Oliff

摘要

In 2011, meibomian gland dysfunction (MGD) was officially recognized as a condition that necessitated treatment with the goal of improving ocular symptoms. This was a tipping point in the understanding of MGD and the need for treatment. After 2011, there was an exponential increase in the research of MGD and treatment modalities. This commentary aims to provide information for clinicians to understand the value of in-office treatments with LipiFlow and the inherent differences in efficacy, patient/doctor experience, compliance, and safety of other treatment modalities. Also, the aim of this commentary is to describe how LipiFlow Thermal Pulsation System contributed to the evolution of MGD management by transforming therapeutic gland expression from an underutilized intervention into a widely adopted, evidence-based standard of care.